Theravance Biopharma to Participate in Upcoming Investor Conferences
- Management will be participating in a Fireside Chat at the
SVB Leerink10th Annual Global Healthcare Conference on Wednesday, February 24at 12:00 p.m. ET( 9:00 a.m. PT/ 5:00 p.m. GMT) Richard A. Graham(Senior Vice President, Development) will be participating in the GI/Microbiome Panelat the Cowen 41st Annual Health Care Conference on Tuesday, March 2at 11:10 a.m. ET( 8:10 a.m. PT/ 4:10 p.m. GMT)
Webcast of the events may be accessed by visiting the "Investors" section of
In pursuit of our purpose, we apply insights and innovation at each stage of our business and utilize our internal capabilities and those of partners around the world. We apply organ-selective expertise to biologically compelling targets to discover and develop medicines designed to treat underserved localized diseases and to limit systemic exposure, in order to maximize patient benefit and minimize risk. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Our pipeline of internally discovered programs is targeted to address significant patient needs.
We have an economic interest in potential future payments from
For more information, please visit www.theravance.com.
View original content to download multimedia:http://www.prnewswire.com/news-releases/theravance-biopharma-to-participate-in-upcoming-investor-conferences-301225449.html